Pushpa Vijayaraghavan, Healthcare Advisory Practice lead at Sathguru Management Consultants participated and moderated a session on “Sustainability & Indian Pharma: 360 degree focus” at the 15th edition of CPhI & PMEC India in New Delhi during 29 November – 1 December 2022.
Focused on demonstrating a new shape of pharmaceutical manufacturing in the post Covid era, CPhI & PMEC India 2022, organized by Informa Markets in India, commenced at the India Expo Centre, Greater Noida, Delhi – NCR.
Started on November 29, the co-located shows provided a unique opportunity to all the stakeholders to discuss the entire range of pharma machinery, analytical instruments, laboratory technologies and equipment, ancillaries, ingredients and more in a hybrid format.
After the successful conclusion of CPhI Pre-Connect Congress on November 28, the 15th edition of CPhI & PMEC India on the theme #GetPharmore with Pharmore opportunities and Pharmore connections, witnessed one of the largest gatherings of industry experts, leading manufacturers, buyers’ community, policy advisors, and other key stakeholders.
The grand inauguration ceremony marked by the presence of key dignitaries Dr. Veeramani SV, vice-chairman Pharmexcil, Alessandro Liberatori, director, Italian Trade Commissions, AVPS Chakravarthi, Ambassador – World Packaging Organisation & board member, Pharmexcil, Bodh Raj Sikri, chairman, Federation of Pharmaceutical Entrepreneurs, Margaret Ma, president & CEO Informa Markets Asia, Chris Eve, executive vice president, Informa Markets Asia; Yogesh Mudras, managing director, Informa Markets in India, Rahul Deshpande, senior group director, Informa Markets in India, and Ranjith Paul, group director, Informa Markets in India.
Speaking on the sidelines of the inaugural, Ravi Uday Bhaskar, director general, Pharmexcil said, “The Indian pharmaceutical exports have recorded an impressive growth of approximately 5 per cent in the current financial year (April-Oct 2022). Despite having global challenges, we have exported over USD 25 billion in the biggest market, which means about 30 per cent of our exports are going to the US. At CPhI & PMEC India, we received a great response with more than 100 pharma companies and 100+ stalls and a huge number of bookings. We are looking forward to participating in the next edition, with a larger floor space and a market size in excess of USD 27 billion for FY23.”
Offering the industry perspective, Dr Veeramani SV, vice-chairman Pharmexcil, said “There is a strong push from the government towards creating an ecosystem for innovation so that India can become a leader in discovery of drugs and medical technology. Currently, the Indian pharmaceutical market is valued at around USD 50 billion, out of which almost USD 25 billion constitutes the export market. CPhI & PMEC India 2022 has provided an unbiased and vocal platform which brings all the key stakeholders on one table and contribute towards the nation’s target, with the vision that the domestic market will touch USD 130 billion by 2030 out of which over 60 per cent will only be exports.”
This year’s edition saw participation of over 40,000 visitors and more than 1,500 exhibitors showcasing 5000+ products across 100,000+ sq m of exhibition space with representation from over 80 + countries. They reaffirmed the need and focus of CPhI & PMEC India India 2022 as an industry event to boost and facilitate the pharmaceutical sector. Key exhibitors include Hetero, Aurobindo, Signet, Teva, Optimus, Lonza Capsules, Merck, IMCD, Fette Compacting, Elmach, ACG, BD Pharma, IMA, Cadmach, GEA and many more.
The expos are primarily supported by industry associations such as Pharmexcil, CIPI, IDMA, ASPA, IPA, IPEC, FOPE and KDPMA.
Addressing the opportunities in this sector, Yogesh Mudras, managing director, Informa Markets in India said, “India’s pharmaceutical sector has done far more than prove itself in terms of manufacturing volumes and emerged as a life sciences leader within the post-pandemic order. India’s pharmaceutical sector is a USD 50 billion industry and is anticipated to grow to at least USD 150 billion in less than a decade. The government is also developing new strategies to strengthen the sector which has led to the creation of innovation hubs making India an ideal testing ground for innovations in digital health.
“Our show CPhI & PMEC India has demonstrated excellence in further supporting the industry by curating highly effective platforms for showcasing technology solutions, knowledge sharing, networking, and advocacy. We are confident that the 15th edition of the show and the other events surrounding it will deliver unprecedented success for all participants of this industry. Furthermore, they will play their role in encouraging the ‘Make in India’ credo of the government that aims to facilitate investment, foster innovation, enhance skill development, protect intellectual property & build best-in-class manufacturing infrastructure,” he further added.
Covid’s impact on the industry was transformative and the pace of the development in the pharma sector took off. The international generics market is projected to grow at a 6 per cent CAGR for the next five years whereas the Indian generics export market has been recording almost 2.5 times growth compared to the global generics market. In that sense, the growth of the Indian pharma industry can be extrapolated to 10 per cent CAGR for the next five years, with exports then possibly reaching USD 40 billion in the next five years.
In addition to this, telehealth and digital health has gained significant importance, along with evolving innovative technologies in healthcare such as AI or robotics. To fully optimize on the available resources and the need to enable the transformation, CPhI & PMEC India provides a quality perspective, encourages the players to take advantage of the sector’s potential and collaborate with industry stakeholders
Alongside the display of the latest technologies, of CPhI & PMEC India, the expertly curated CEO Roundtable has been envisaged to bring forth innovations in the pharma sector and discussed how Indian pharma companies can achieve a global leadership in value that is being generated. The topics discussed were ‘Competing with developed countries by optimizing manufacturing and supply chain’ and ‘Accelerating research in complex generics and new chemical entities to be on map with global innovators’. The evening of Day 1 will also witness the 9th Annual India pharma awards to further support and encourage industry players, who strive hard to bring about a sea change in the pharmaceutical domain with ground-breaking innovations and initiatives. Day 2 will see Women in Pharma Roundtable which is an initiative aimed at acknowledging and celebrating the significant and continued contribution of women to the pharmaceutical industry in a closed-door roundtable discussion.
The series of sessions offered integration and adoption of transformative technologies offering lucrative opportunities in this sector. A comprehensive list of speakers at the show included Dr. Hamada Sherief, general director, Egyptian Drug Authority (EDA); Yasuhiro Sensho, director, SENSHO-GUMI Co Ltd; Dr. Sanjit Singh Lamba, CEO and founder – Biocuris; Dr. Shubhadeep D Sinha, senior vice-president & medical director, Hetero Drugs; Udaya Bhaskar, director general, Pharmexcil; Pushpa Vijayaraghavan, director, Sathguru Management Consultants and Dr Ralph Tettey-Amlalo (Ph.D., MBA), managing director – HG&H Pharmaceuticals (Pty) Ltd, Johannesburg – South Africa among others added synergistic value to the B2B trade show. The three-day seminar and conference hosted a plethora of government officials, experts, industry associations and evangelists, and technical leaders shaping the future of the pharma industry. It was a perfect convergence of experts from public and private sectors.